Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis by unknown
Osterhaus and Purcaru Arthritis Research & Therapy 2014, 16:R164
http://arthritis-research.com/content/16/4/R164RESEARCH ARTICLE Open AccessDiscriminant validity, responsiveness and reliability
of the arthritis-specific Work Productivity Survey
assessing workplace and household productivity
within and outside the home in patients with axial
spondyloarthritis, including nonradiographic axial
spondyloarthritis and ankylosing spondylitis
Jane T Osterhaus1* and Oana Purcaru2Abstract
Introduction: The arthritis-specific Work Productivity Survey (WPS) was developed to evaluate productivity limitations
associated with arthritis within and outside the home. There is an unmet need for an instrument assessing similar
productivity limitations in axial spondyloarthritis (axSpA), including nonradiographic axSpA and ankylosing spondylitis.
Following its validation in rheumatoid and psoriatic arthritis, we aimed to assess psychometric properties of WPS in
adult-onset active axSpA in this analysis.
Methods: Psychometric properties were assessed using data from the RAPID-axSpA trial (NCT01087762) in which
researchers investigated certolizumab pegol efficacy and safety in axSpA. WPS was completed at baseline and every
4 weeks until week 24. Validity was evaluated at study baseline via known-groups defined by the first and third quartile
cutoffs of patient scores to Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), back pain, Bath Ankylosing Spondylitis Functional Index (BASFI), Short Form 36 health survey
(SF-36) and Ankylosing Spondylitis Quality of Life Scale (ASQoL). Responsiveness and reliability were assessed by
comparing WPS mean changes in ASAS 20% improvement criteria (ASAS20), BASDAI50, ASDAS clinically important
improvement/major improvement (CII/MI) and BASFI minimum clinically important difference (MCID) responders
versus nonresponders at week 12. All comparisons were conducted on observed cases in the randomized set using a
nonparametric bootstrap-t method.
Results: The results confirmed the psychometric properties of WPS. AxSpA patients with a worse health state had
significantly more days of household work lost, household work with reduced productivity, social activities missed and
outside help hired, as well as a higher interference rate of arthritis, than patients with a better health state. Similarly,
employed patients with a worse health state had significantly more work days lost or with productivity reduced, and a
higher interference of arthritis on work productivity. Similar findings were also observed in the nonradiographic (nr)
axSpA and AS subpopulations. The WPS was responsive to clinical changes, with responders reporting larger
improvements at week 12 in WPS scores versus nonresponders. Effect sizes in responders were generally moderate
to large (standardized response mean >0.5).
Conclusions: These analyses demonstrate that WPS is a valid, responsive and reliable instrument for the measurement
of productivity within and outside the home in adult-onset axSpA, as well as the in subpopulations of AS and nr-axSpA.* Correspondence: jtosterhaus@mindspring.com
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Axial spondyloarthritis (axSpA) refers to spondyloarthritis
with predominantly axial involvement and comprises the
well-known disease subgroup ankylosing spondylitis (AS),
as well as a disease subgroup with little or no changes on
plain radiographs, referred to as nonradiographic axial
spondyloarthritis (nr-axSpA). Nr-axSpA and AS can be
considered opposite ends of the same disease spectrum
[1]. According to this concept, the presence of radio-
graphic changes in the sacroiliac joints (and the presence
of syndesmophytes in the spine) should be regarded as
markers of disease progression and severity rather than as
essential diagnostic criteria.
AS, the most frequently investigated subset of axSpA,
is a chronic inflammatory rheumatic disease that affects
approximately twice as many men as women and has a
disease onset usually in the second and third decades of
life. The prevalence of AS worldwide ranges from 0.1%
to 1.4% [2-4]. The prevalence of spondyloarthritis in the
United States was recently shown to be 1.4% [5]. Disabil-
ity in AS is related to the degree of inflammatory activity
causing pain, stiffness, fatigue and poor quality of sleep,
as well as to the degree of bony ankylosis causing loss of
spinal mobility. During early disease stages, disability is
determined mostly by inflammatory activity, whereas in
long-standing disease, both inflammation and ankylosis
contribute to disability. The average time between onset
of symptoms and definite disease diagnosis of AS has
been reported to be up to 9 years [6]. At least 30% of pa-
tients have severe disease which is often associated with
considerable loss of function.
Two of the common symptoms associated with AS—
pain and fatigue—are expected to impact work-related per-
formance. Fatigue in patients with AS has been reported
to be associated with limitations in daily life, functioning,
pain and stiffness, as well as with global well-being and
mental health [7]. AS patients in one study ranked “impact
on work” as the area of their life most affected by their
condition [8].
It has been reported that the costs associated with
work disability or productivity losses at paid work (indir-
ect costs) of AS are higher in some countries than the
direct medical costs [9]. In a recently reported study
conducted in the Netherlands of patients with AS under
the care of rheumatologists, 11.6% of patients with paid
work had an episode of AS-related sick leave in the pre-
vious 2 weeks (absenteeism) and just over 50% felt their
work was adversely influenced by AS, suggesting a sig-
nificant impact on presenteeism [10]. In the entire sam-
ple, 71% experienced restrictions in different types of
unpaid tasks. Limitations in physical function were con-
sistently associated with work outcome.
The key goals of treatment in AS include control of pain
and stiffness, as well as reducing damage, disability andloss of function. Given that AS tends to occur in the sec-
ond and third decades of life, it is expected that many
people initially diagnosed with AS are in the midst of their
working careers. In a 2001 review, Boonen et al. summa-
rized findings on work participation among AS patients in
different countries [11]. The proportion of patients in em-
ployment ranged from 34% to 96%, and the proportion of
patients with work disability ranged from 3% to 50%.
In order to fully quantify the impact of an intervention on
productivity, it is crucial to consider the entire productivity
continuum, both within the work environment and within
the home [12]. Preventing disability and loss of function
may improve a patient’s ability to stay in the workforce or
maintain the ability to live independently at home. There-
fore, there is interest in understanding the impact of axSpA
and potential axSpA treatments on work-related productiv-
ity, including paid work as well as household work.
Historically, there has been an unmet need for an in-
strument designed to assess presenteeism and absentee-
ism in both the work and home environments [13-16].
The arthritis-specific Work Productivity Survey (WPS)
was developed to fulfill the unmet need for an arthritis-
specific instrument to assess the impact of an intervention
on productivity within the work and home environments,
in addition to daily activities during the preceding month
[17]. Details of the development of the WPS are reported
elsewhere [17]. The WPS has demonstrated properties of
discriminative validity, reliability and responsiveness for
the measurement of productivity within and outside the
home in patients with active rheumatoid arthritis (RA)
and psoriatic arthritis (PsA) [17-19].
There is no gold standard measure for assessing prod-
uctivity in axSpA. During the Outcome Measures in
Rheumatology (OMERACT) 9 meeting, the WPS was
one of six instruments identified by the OMERACT
Worker Productivity group as a possible candidate for
assessing worker productivity changes in rheumatology,
based on the available filter evidence (truth, discrimin-
ation and feasibility) [20].
The WPS was selected to measure the impact of axSpA
on workplace and household productivity, as well as on
participation in daily activities, because of the ease of use
and positive response in terms of psychometric properties
seen in rheumatoid arthritis (RA) [17], and the similarity
in terms of work disability associated with RA and axSpA.
Our objective in writing this article was to assess the
discriminant validity, responsiveness and reliability of
the Work Productivity Survey in adult-onset active
axSpA, as well as in AS and nr-axSpA subpopulations.
Methods
Patients and study design
Data from the double-blind period of the RAPID-axSpA
(efficacy and safety of certolizumab pegol (CZP) in
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week 24, dose-blind to week 48 and then open-label to
week 204) were used to conduct the psychometric valid-
ation of WPS [21]. In the first 24 weeks of RAPID-
axSpA, CZP 200 mg every 2 weeks (Q2W), 400 mg
every 4 weeks (Q4W) or placebo were investigated. The
trial was conducted at 83 centers across North America,
Latin America, Western Europe and Central/Eastern
Europe from March 2010 to October 2011. Institutional
review boards or ethics committees approved the proto-
col at each center (see Additional file 1). All patients
gave written consent, and the study was conducted in
accordance with the Declaration of Helsinki [21].
Patients were randomly assigned 1:1:1 to receive (1) pla-
cebo (saline) Q2W, or subcutaneous CZP 400 mg at
Weeks 0, 2 and 4 (loading dose) followed by either (2) 200
mg CZP Q2W or (3) 400 mg CZP Q4W until Week 24.
Placebo patients who did not achieve at least Assessment
of SpondyloArthritis International Society (ASAS) 20%
improvement criteria (ASAS20) response at both week 14
and week 16 remained blinded, but were rerandomized to
active treatment at week 16 in a 1:1 ratio (CZP 200 mg
Q2W or CZP 400 mg Q4W) and received the loading
dose at weeks 16, 18 and 20. CZP patients continued to
receive the initially assigned dose [21].
The primary efficacy endpoint was the ASAS20 re-
sponse at week 12 [22,23]. Secondary and exploratory
endpoints included the ASAS40, ASAS50, ASAS70,
Total and Nocturnal Spinal Pain, physical functioning
assessed by Bath Ankylosing Spondylitis Functional
Index (BASFI), Bath Ankylosing Spondylitis Disease Ac-
tivity Index (BASDAI) and Ankylosing Spondylitis Dis-
ease Activity Score (ASDAS), health-related quality of
life (HRQoL), assessed using the Short Form 36-item
health survey (SF-36), EuroQoL 5 dimensions (EQ-5D)
and the Ankylosing Spondylitis Quality of Life Scale
(ASQoL), and productivity measured using the WPS.
Questionnaires
The WPS is a disease-specific questionnaire used to assess
the impact of arthritis on workplace and household prod-
uctivity, as well as daily activities during the preceding
month. It is interviewer-administered and self-reported by
the patient and has a 1-month recall period [17].
The first item of the WPS addresses current labor
market participation (employment outside the home), as
well as providing normative and comparative data on
employment status. This is a strong indicator of ability
to work, because not working implies complete loss of
paid productivity. Two items capture self-reported ab-
senteeism (days of work missed) and presenteeism (days
with productivity reduced by at least half ) due to arth-
ritis, and two items capture the same concepts but apply
to nonpaid (household) work. Additional items capturethe respondent’s estimate of the extent to which arthritis
has interfered with work productivity (paid and nonpaid)
on a scale of 0 to 10 (0 = no interference and 10 =
complete interference), the number of days in the past
month that outside help was hired because of arthritis,
and the number of days in the past month family, social
or leisure activities were missed because of arthritis [17].
The ASDAS is a composite score derived from a num-
ber of assessments, which are scored by the subject and
physician and multiplied by a proven formula, with
lower scores indicating low disease activity [24]. The
BASFI comprises 10 items assessing physical function
over the preceding week [25]. The summary score from
this scale is the mean of the 10 items and ranges from 0
to 10, with 0 representing the best state (lower disease
activity) and 10 the worst state. The minimum clinically
important difference (MCID) for BASFI is one point.
The BASDAI is the most commonly used instrument
to measure the disease activity of ankylosing spondylitis
over the preceding week, and ranges from 0 to 10, with
0 representing the best state and 10 the worst state. The
BASDAI50 is defined as an improvement of at least 50%
in the BASDAI compared to baseline. A response criter-
ion for the BASDAI is defined by an MCID decrease of
at least one [26].
Total and Nocturnal Spinal Pain are assessed by two
questions rated on a 0 to 10 numerical rating scale (NRS),
where 0 = no pain and 10 =most severe pain. The ASQoL
is an 18-item questionnaire, each item of which is used to
assess the patient’s current opinion on his or her quality of
life [27]. Each item is scored as 1 = yes or 0 = no. The
summary score is the total of the yes and no scores, thus
ranging from 0 (best HRQoL) to 18 (worst HRQoL).
The SF-36 is a widely used generic HRQoL instrument
used to evaluate eight health domains: physical function-
ing, role physical, bodily pain, general health, vitality, so-
cial functioning, role emotional and mental health [28].
The eight domains are summarized in two component
summaries: the Physical Component Summary (PCS) and
the Mental Component Summary (MCS) [26]. Scores on
the SF-36 range between 0 and 100, with higher scores in-
dicating a better HRQoL.
The EQ-5D questionnaire is comprised of a five-item
health status measure and a Visual Analogue Scale
(VAS). Each of the five dimensions is divided into three
levels: no problem, some or moderate problems and ex-
treme problems, scored as 1, 2, and 3, respectively. The
EQ-5D VAS records the respondent’s self-rated health
status on a vertical 20-cm scale, 0 to 100 graduated (0 =
worst imaginable health status and 100 = best imaginable
health status).
The ASAS20 response is defined as an improvement
of at least 20% and absolute improvement of at least one
unit on a 0 to 10 NRS in at least three of four domains:
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pain NRS score, BASFI and mean of BASDAI questions
5 and 6 concerning morning stiffness intensity and dur-
ation and the absence of deterioration in the potential
remaining domain, with deterioration defined as a relative
worsening of at least 20% and an absolute worsening of at
least one unit [29].
The ASAS criteria for 40%, 50% or 70% improvement
are defined as relative improvements of at least 40%,
50% or 70% and absolute improvement of at least two
units on a 0 to 10 NRS in at least three of the four do-
mains and no worsening at all in the remaining domain.
Further details of the questionnaires assessed are in-
cluded in Additional file 2.
Data handling and statistical analysis
The assessment of the psychometric properties (discrim-
inant validity, responsiveness and reliability) of the WPS
was performed on the overall axSpA randomized set
(RS) population, regardless of the randomization group.
Analyses were also performed on the nr-axSpA and AS
subpopulations separately.
Discriminant validity
Given the nature of the WPS questionnaire, which is
composed of several single-global questions, scored and
interpreted separately, and the length of the recall period
of these questions, the construct validity of the WPS
questionnaire was evaluated by means of discriminant
validity using correlations and the known-groups valid-
ation method. The association between the responses to
the WPS questions (Q)2 to Q9 and scores of the different
measures of disease activity, physical functioning or
HRQoL was assessed using Kendall correlation coeffi-
cients. Given the difference between the concepts assessed
by the WPS questions and the other measures considered,
the correlation coefficients are expected a priori to be low
to moderate (low = 0 to 0.3, moderate ≥0.3 to <0.5), thus
indicating a divergent validity of the measures compared.
High correlations could imply a low discriminant validity
and suggest that two items are measuring similar con-
cepts. The Kendall association coefficients were evaluated
between WPS Q2 to Q9 and the following selected mea-
sures: ASDAS, BASDAI, BASFI, total/nocturnal spine
pain, SF-36 MCS, PCS and domains, ASQoL, fatigue NRS
(from BASDAI) and EQ-5D VAS.
The known-groups validity method was used to com-
pare the productivity scores between patients with a
worse health state versus patients with a better health
state. A patient with a worse health state was considered
to be a patient with a higher disease activity, a worse
HRQoL level or a lower physical functioning level,
whereas a patient with a better health state was defined
as having either a lower disease activity, a better HRQoLor a higher physical functioning level, respectively. The
assumption tested through the known-groups validity
method was that patients with a worse health state were
expected a priori to have higher losses in paid and
household work productivity (that is, higher WPS scores
to Q2 to Q9) due to their disease, compared with pa-
tients in a better health state. For this purpose, known
groups were formed using the first- and third-quartile
scores for each outcome as cutoff points in order to
avoid comparison of unbalanced groups [17]. Patients
with baseline SF-36 scores at or above the third quartile,
or ASQoL or fatigue NRS (from BASDAI) scores at or
below the first quartile, were considered to have a “bet-
ter” HRQoL, and those with SF-36 scores at or below
the first quartile or ASQoL or fatigue NRS scores at or
above the third quartile were defined as having “worse”
HRQoL. Similarly, “better” and “worse” physical function
were defined as BASFI scores at or below the first quartile
and at or above the third quartile, or SF-36 physical func-
tion or SF-36 PCS scores at or above the third quartile
and at or below the first quartile, respectively. Patients
with ASDAS, BASDAI, or total/nocturnal spine pain score
at or below the first quartile were considered to have
“low” disease activity/severity, whereas ASDAS, BASDAI,
or total/nocturnal spine pain score at or above the third
quartile indicated “high” disease activity/severity.
The discriminant validity of the WPS was assessed using
baseline observed data. To test the validity of productivity
at paid work (WPS Q2-Q4), cutoff points were computed
only on the patients employed outside the home, whereas
the thresholds were computed on all patients for product-
ivity within the home (Q5-Q9). Sensitivity analyses were
performed using a median cutoff threshold.
A nonparametric bootstrap-t method was used to
compare the mean WPS question responses between the
known groups [30]. This method was favored because of
the highly skewed distribution of the WPS scores. Boot-
strap analyses were performed with 10,000 replications.
A variance stabilizing transformation was used in order
to adjust for dependence between the bootstrap values
and the corresponding standard error.
Responsiveness to clinical changes and reliability
The responsiveness of the WPS to clinical changes in a
patient’s condition over time was evaluated by comparing
the changes from baseline in productivity scores between
clinical responders versus nonresponders at week 12 (as
measured by ASAS20 criteria). The assumption tested was
that clinical responders would have higher improvements
in productivity at work outside the home and within
the household versus nonresponders, reflected by higher
negative changes (in absolute value) in WPS scores.
According to the primary analysis, patients were con-
sidered a “responder” if they met the criteria of ASAS20
Table 1 Baseline demographics and clinical characteristics
in axial spondyloarthritis, ankylosing spondylitis and
nonradiographic axial spondyloarthritis populations














Sex, % male 61.5 72.5 48.3
Race, % white 90.2 89.3 91.2
Disease characteristics






















Positive for HLA-B27, n (%) 255 (78.5) 145 (81.5) 110 (74.8)
BASDAI 6.5 ± 1.6 6.4 ± 1.6 6.5 ± 1.5
BASFI 5.4 ± 2.2 5.7 ± 2.2 4.9 ± 2.3
BASMI 3.8 ± 1.7 4.4 ± 1.7 3.2 ± 1.5
ASDAS 3.8 ± 1.0 3.9 ± 0.9 3.7 ± 1.0
Total spine paind 7.0 ± 1.9 7.1 ± 1.9 7.0 ± 1.9
Nocturnal spine paind 6.9 ± 2.3 6.9 ± 2.2 6.9 ± 2.5
Prior TNF inhibitor exposure, % 16.0 20.2 10.9
Health-related quality of life
Fatigue NRSd 6.7 ± 1.9 6.6 ± 2.0 6.7 ± 1.8






















aASDAS: Ankylosing spondylitis disease activity scale; ASQoL: Ankylosing
spondylitis quality of life; axSpA, Axial spondyloarthritis; BASDAI: Bath
ankylosing spondylitis disease activity index; BASFI: Bath ankylosing spondylitis
functional index; BASMI: Bath ankylosing spondylitis metrology index; CRP:
C-reactive protein; EQ-5D: EuroQoL 5 dimensions; HLA: Human leukocyte
antigen; MCS: Mental component summary; nr-axSpA, Nonradiographic axial
spondyloarthritis; NRS: Numerical rating scale; PCS: Physical component summary;
SF-36: Short form 36 item; TNF: Tumor necrosis factor; VAS: Visual analogue scale.
bFrom the start date of the primary disease. cNormal range of CRP <8.0 mg/L.
dIn full analysis set population: n = 324 axSpA, 178 AS, 146 nr-axSpA. Except
where indicated otherwise, values are the mean ± SD. There were no significant
differences between treatment groups at baseline.
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did not meet the criteria for ASAS20 was considered a
“nonresponder”.
The reliability of the WPS was tested in conjunction
with the responsiveness to the ASAS20 clinical response
by comparing the changes in WPS scores in patients
achieving ASAS40, ASAS50, BASDAI50, ASDAS major
improvement (MI), ASDAS clinically important improve-
ment (CII), total/nocturnal back pain MCID and BASFI
MCID responses at week 12 versus nonresponders.
WPS score changes from baseline at week 12 were com-
pared between week 12 clinical responders versus nonre-
sponders using a nonparametric bootstrap-t method. A
variance stabilizing transformation was used in order to
adjust for dependence observed between bootstrap values
and the corresponding standard error. Bootstrap analyses
were performed with 10,000 replications.
In addition to the comparison of the changes in WPS
scores between the clinical responders and nonresponders,
the standardized response mean (SRM) was calculated.
The SRM is one of the most widely used measures of the
effect size of the response, indicating whether the change
was large relative to the variability of the measurements.
The SRM is estimated as the mean change in scores be-
tween two visits divided by the standard deviation of that
change in scores. Thresholds for the SRM (absolute
values) were proposed by Cohen [31] to interpret the size
of the effects: “small” from 0.2 to 0.5, “moderate” from 0.5
to 0.8 and “large” greater than 0.8.
The responsiveness and reliability of the WPS was




A total of 325 patients were randomized, and 298 (91.7%)
patients completed the 24-week phase. In the overall
axSpA population, RS patients had a mean age of approxi-
mately 39.6 years, with 78.8% of patients between ages 25
and 54 years. Over half (61.5%) of the patients were male,
and most (90.2%) were white (Table 1). In the AS subpop-
ulation, the mean age (41.5 years) was higher compared to
the nr-axSpA subpopulation (37.4 years), and AS patients
were also more likely to be male compared to nr-axSpA
patients (72.5% versus 48.3%, respectively) (Table 1).
Patients in the overall axSpA population reported a
median time since disease diagnosis of 3.9 years. In the
AS subpopulation, the median time since diagnosis was
5.5 years, and for the nr-axSpA subpopulation it was
2.5 years (Table 1). The majority (78.5%) of patients in the
overall axSpA population tested positive for human
leukocyte antigen (HLA) B27; this was also true for
the AS and nr-axSpA subpopulations (81.5% and 74.8%,
respectively). In general, BASDAI scores were similar,whereas BASMI and BASFI scores were lower, in the nr-
axSpA subpopulation relative to the AS subpopulation, in-
dicating comparable disease burden but less limitation in
function and mobility in patients with nr-axSpA (Table 1).
Whereas the largest percentage of patients in the
overall axSpA population and AS subpopulation were
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patients in the nr-axSpA subpopulation were more evenly
distributed among North Americans (27.2%), Western
Europeans (34.7%), and Eastern Europeans (29.3%).
At baseline, 69.2% of patients in the overall axSpA
population were employed outside the home, 12.3%
were unable to work due to axSpA, 5.8% were students
and 5.5% were retired. The rest were homemakers
(3.1%), unable to work due to non-axSpA health prob-
lems (1.9%) or had other nonemployment status (2.2%)
(Table 2). Generally similar employment rates were
noted in the nr-axSpA and AS subpopulation, although
in the nr-axSpA subpopulation there were slightly more
patients employed outside the home, homemakers or
students, as well as fewer patients who were unable to
work due to arthritis or were retired compared to the
AS subpopulation (Table 2).
Baseline productivity within and outside the home
The burden of axSpA at study baseline was high,
impacting workplace absenteeism and presenteeism as
well as household productivity and participation in daily
activities (Table 3).
Patients in jobs with some manual component had a
higher number of workplace days missed per month
than those in exclusively nonmanual jobs (mean 2.5
versus 1.4 days). Additionally, these patients reported
more days per month with patient workplace productivityTable 2 Employment status at baseline in axial
spondyloarthritis, ankylosing spondylitis and
nonradiographic axial spondyloarthritis populations







Employment status, n (%)
Employed outside the home 225 (69.2) 120 (67.4) 105 (71.4)
Not employed outside home
Homemakers 10 (3.1) 4 (2.2) 6 (4.1)
Retired 18 (5.5) 12 (6.7) 6 (4.1)
Student 19 (5.8) 6 (3.4) 13 (8.8)
Unable to work due to arthritis 40 (12.3) 28 (15.7) 12 (8.2)
Unable to work due to
non-arthritis-related health
problems
6 (1.8) 5 (2.8) 1 (0.7)
Other nonemployed status 7 (2.2) 3 (1.7) 4 (2.7)
Job function if employed, n (%)
Nonmanual 109 (48.4) 53 (44.2) 56 (53.3)
Mixed (manual and nonmanual) 73 (32.4) 40 (33.3) 33 (31.4)
Manual with no supervisory duties 43 (19.1) 27 (22.5) 16 (15.2)
aAS, Ankylosing spondylitis; axSpA, Axial spondyloarthritis, nr-axSpA, Nonradiographic
axial spondyloarthritis. Employment status was captured through the Work
Productivity Survey.reduced by at least half compared to those with exclusively
nonmanual jobs (mean 6.1 versus 4.3 days, respectively).
In terms of household work, employed patients reported
a high impact of axSpA symptoms, but the impact was
lower compared to nonemployed patients and to patients
unable to work due to arthritis (mean household work
days missed per month: 4.6 versus 8.4 versus 14.6; mean
days per month with household productivity reduced
by ≥50%: 6.6 versus 9.4 versus 11.2, respectively).Completion rates of Work Productivity Survey at baseline
At baseline, all patients in the axSpA RS population an-
swered at least one of the WPS questions. The comple-
tion rates of each of the WPS questions at baseline in
the RS population were very high, indicating that the in-
strument was clear, acceptable and representative of the
study population, and therefore that the results can be
generalized to a larger axSpA population. There was
only one (0.3%) missing answer to WPS Q5 to Q9 at
baseline. Among all employed axSpA RS patients who
were required to answer WPS Q2 through Q4, the com-
pletion rates at baseline were also high, with only two
(0.9%) missing answers for Q2 and three (1.3%) missing
answers for Q3 and Q4.
Similarly high completion rates of WPS questions were
noted in the nr-axSpA and AS subpopulations. At base-
line, there was no presence of a ceiling effect, as shown
by the very small number of patients with a maximal an-
swer. In the overall axSpA population, two (0.9%) to four
(1.8%) of the RS employed patients had an answer ≥30
days to WPS Q2 and Q3, respectively, and ten (4.5%)
had a maximum answer of 10 to Q4. Out of all RS pa-
tients, 5 (1.5%) to 21 (6.5%) had an answer ≥30 days to
WPS Q5 to Q8 or a maximal score of 10 to Q9. Simi-
larly, no ceiling effects were noted in the nr-axSpA and
AS subpopulations.
As expected, in terms of floor effect, the percentage of
patients with a minimal response varied between the WPS
questions, with a higher number of patients answering 0
to Q2 (work days missed in the past month, 69.5% of the
employed RS population in the overall axSpA population)
and to Q8 (days with outside help hired, 78.1% of the en-
tire RS population), and ranging from 11.3% to 50.5% for
the other questions. Similar results were observed in the
nr-axSpA and AS subpopulations.Discriminant validity
The association coefficients between all WPS questions
and different continuous measures assessing the disease
activity, physical functioning and HRQoL, were low
(<0.3) to moderate (≥0.3 to 0.5), as expected, indicating
divergent validity between the individual WPS questions
and the other measures considered (Figure 1).
Table 3 Workplace and household productivity at baseline in axial spondyloarthritis, ankylosing spondylitis and
nonradiographic axial spondyloarthritis populations (randomized sets, observed cases)a
axSpA (n = 324) AS (n = 178) nr-axSpA (n = 146)
WPS questionsb n Mean (SD) Median n Mean (SD) Median n Mean (SD) Median
Q2. Number of days of work missed (absenteeism)c 223 2.0 (4.8) 0.0 119 1.6 (3.5) 0.0 104 2.5 (6.0) 0.0
Q3. Number of days with productivity ≤50% at work
(presenteeism)c,d
222 5.2 (7.6) 0.0 119 4.7 (7.1) 0.0 103 5.8 (8.0) 2.0
Q4. Rate of arthritis interference with work productivityc,e 222 4.6 (2.6) 5.0 119 4.5 (2.4) 5.0 103 4.8 (2.9) 5.0
Q5. Number of days of household work missed 324 5.8 (8.3) 2.0 178 5.2 (7.7) 1.0 146 6.5 (8.8) 3.0
Q6. Number of days with productivity ≤50% in household workd 324 7.5 (8.9) 5.0 178 7.0 (8.6) 4.0 146 8.1 (9.2) 5.0
Q7. Number of days of family, social or leisure activities missed 324 4.4 (6.9) 1.0 178 3.6 (6.1) 0.5 146 5.4 (7.8) 2.0
Q8. Number of days with outside help 324 2.1 (5.8) 0.0 178 1.6 (4.8) 0.0 146 2.7 (6.8) 0.0
Q9. Rate of arthritis interference with household work productivitye 324 4.9 (2.9) 5.0 178 4.9 (2.7) 5.0 146 4.8 (3.2) 5.0
aAS, Ankylosing spondylitis; axSpA, Axial spondyloarthritis, nr-axSpA, Nonradiographic axial spondyloarthritis. bRecall period for Work Productivity Survey is
1 month. cAssessed in employed patients only. dDays counted exclude those counted in previous question (full days missed). eScored from 0 to 10, where 0 = no
interference and 10 = complete interference.
Figure 1 Kendall association coefficients between Work Productivity Survey and clinical and health-related quality of life assessments
at baseline (randomized set, observed cases). Selective results of Kendall association coefficients are presented. (A) Work Productivity Survey
(WPS) Question (Q)2 (number of work days missed because of arthritis). (B) WPS Q4 (rate of arthritis interference with work productivity. (C) WPS
Q5 (number of days with no household work because of arthritis). (D) WPS Q9 (rate of arthritis interference with household work productivity).
WPS Q2 and Q4 were assessed in employed patients only, whereas Q5 and Q9 were assessed in all patients. Q4 and Q9 are scored on a scale of
0 to 10 points (0 = no interference and 10 = complete interference). Correlation level (absolute value): low correlation (<0.3); moderate correlation
(≥0.3 to <0.5). Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), Total/Nocturnal Spine Pain, Ankylosing Spondylitis Quality of Life Scale (ASQoL): lower score = better.
Short Form 36 items (SF-36), EuroQoL 5 dimensions Visual Analogue Scale (EQ-5D VAS): higher score = better. WP: Work productivity.
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Table 4 Work Productivity Survey baseline scores by defined known-groups: workplace productivity (randomized set,
observed cases)a
Instrumentb Number of days of
work missed over the
previous month, mean
Number of days with productivity
≤50% at work over the previous
month, mean
Rate of arthritis interference
with work productivity over
previous month, meanc
Worse Better Worse Better Worse Better
BASDAI
axSpA (cutoff 5.20 and 7.50) 3.27d 0.70 7.95d 2.86 5.44d 3.45
n = 59 n = 57 n = 59 n = 57 n = 59 n = 57
AS (cutoff 5.20 and 7.30) 3.12d 0.56 8.12d 2.79 5.32e 3.71
n = 34 n = 34 n = 34 n = 34 n = 34 n = 34
nr-axSpA (cutoff 5.40 and 7.60) 3.19f 0.79 9.63f 3.85 5.74d 3.26
n = 27 n = 28 n = 27 n = 28 n = 27 n = 28
BASFI
axSpA (cutoff 3.80 and 6.55) 4.02d 0.68 7.34f 4.22 5.79d 3.55
n = 56 n = 56 n = 56 n = 56 n = 56 n = 56
AS (cutoff 4.30 and 6.80) 3.09e 0.87 5.47 2.73 5.31d 3.40
n = 32 n = 30 n = 32 n = 30 n = 32 n = 30
nr-axSpA (cutoff 3.20 and 6.40) 6.04d 0.44 8.81 5.25 6.52# 3.63
n = 27 n = 25 n = 27 n = 25 n = 27 n = 25
Total Spine Pain
axSpA (cutoff 6 and 8) 2.97e 1.10 7.01d 2.99 5.57d 3.75
n = 88 n = 82 n = 88 n = 82 n = 88 n = 82
AS (cutoff 6 and 8) 2.87d 0.52 6.40e 2.50 5.17e 3.90
n = 47 n = 42 n = 47 n = 42 n = 47 n = 42
nr-axSpA (cutoff 6 and 8) 3.07 1.70 7.71e 3.51 6.02d 3.59
n = 41 n = 40 n = 41 n = 40 n = 41 n = 40
SF-36 PCS
axSpA (cutoff 37.54 and 27.49) 2.85e 0.76 6.13f* 2.98 5.85d 3.28
n = 54 n = 55 n = 54 n = 55 n = 54 n = 55
AS (cutoff 37.44 and 27.93) 2.72e 0.62 6.48 2.86 5.62d 3.41
n = 29 n = 29 n = 29 n = 29 n = 29 n = 29
nr-axSpA (cutoff 37.76 and 26.58) 3.84f 0.92 6.52 3.12 6.64d 3.12
n = 25 n = 26 n = 25 n = 26 n = 25 n = 26
SF-36 MCS
axSpA (cutoff 49.84 and 32.24) 4.78d 0.81 8.18e 3.54 5.58e 3.93
n = 55 n = 80 n = 55 n = 80 n = 55 n = 80
AS (cutoff 52.73 and 32.87) 3.86e 0.89 7.00f 3.00 5.07 4.18
n = 29 n = 28 n = 29 n = 28 n = 29 n = 28
nr-axSpA (cutoff 46.98 and 30.79) 5.65d 0.69 8.58e 3.23 6.08e 3.50
n = 26 n = 26 n = 26 n = 26 n = 26 n = 26
ASQoL
axSpA (cutoff 8.50 and 15.00) 4.40d 0.62 8.00d 3.35 6.26d 2.98
n = 58 n = 90 n = 58 n = 90 n = 58 n = 90
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Table 4 Work Productivity Survey baseline scores by defined known-groups: workplace productivity (randomized set,
observed cases)a (Continued)
AS (cutoff 8.00 and 14.91) 3.77d 0.42 7.53 3.61 5.73d 3.03
n = 30 n = 31 n = 30 n = 31 n = 30 n = 31
nr-axSpA (cutoff 9.00 and 15.00) 5.07d 0.77 8.50e 3.33 6.82d 3.00
n = 28 n = 30 n = 28 n = 30 n = 28 n = 30
aASQoL: Ankylosing spondylitis quality of life; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index;
MCS: Mental Components Summary; PCS: Physical Components Summary; SF-36: Short form 36 items. bCutoff points represent the first and third quartiles of
baseline scores: “Worse” state is defined for each individual measure as BASDAI score at or above the third quartile; BASFI score at or above the third quartile;
Total Spine Pain score at or above the third quartile; ASQoL at or above the third quartile; SF-36 MCS at or below the first quartile; SF-36 PCS at or below the
first quartile; “Better” state defined for each individual measure as BASDAI score at or below the first quartile; BASFI score at or below the first quartile; Total
Spine Pain score at or below the first quartile; ASQoL score at or below the first quartile; SF-36 MCS, PCS at or above the third quartile; cWPS Q4 is scored on a 0
to 10 scale, where 0 = no interference and 10 = complete interference. dP ≤ 0.001; eP ≤ 0.01; fP ≤ 0.05; nonparametric bootstrap-t method with a variance stabilizing
transformation, 10,000 replications.
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Kendall association coefficients indicated that better
productivity at work and within the home (as assessed
by lower scores to WPS Q2 to Q9) was associated
with better HRQoL, less fatigue, better physical func-
tioning or less pain (Figure 1). The range of the associ-
ation coefficients between the individual WPS questions
and the clinical and HRQoL assessments was similar in
the overall axSpA, nr-axSpA and AS populations. Never-
theless, higher correlation coefficients were observed in
nr-axSpA compared to AS between WPS Q4 (arthritis
interference with work productivity (outside home)) and
all clinical and HRQoL measures, as well as between Q8
(days with outside help hired) and certain HRQoL mea-
sures (SF-36 and ASQoL) (Figure 1).
The known-groups validity analysis indicated that
there was a higher burden of arthritis on productivity at
both paid work and within the home in patients with a
worse health state compared to patients with a better
health state (Tables 4 and 5). Among employed patients
in the overall axSpA population, patients with a worse
health state had higher workplace productivity losses,
with significantly more work days lost and more work
days with productivity reduced by half, and a statistically
higher interference of arthritis on work productivity
compared to patients with a better health state (Table 4).
In the overall axSpA population, compared with patients
with a better health state, patients with a worse health
state had larger productivity losses within the household,
with, on average, significantly more days of household
work lost; more days with household productivity re-
duced by at least half; more days missed of family, social
or leisure activities; more days with outside help hired;
and a significantly higher interference of arthritis (all per
month) (Table 5).
Similar findings were observed in the nr-axSpA and
AS subpopulations, where patients with a worse health
state had a higher burden of arthritis on productivity, at
both paid work and within home, compared to patients
with a better health state (Tables 4 and 5).Responsiveness and reliability
Work Productivity Survey changes from baseline by
SpondyloArthritis International Society (ASAS) 20%
improvement criteria response at week 12
Significantly larger improvements in productivity within and
outside the home (corresponding to higher negative mean
changes in WPS responses) were reported by ASAS20 re-
sponders at week 12 compared to ASAS20 nonresponders
in the overall axSpA population, except with regard to ab-
senteeism, presenteeism and days missed of family, social
or leisure activities, where only numerical differences
were seen (Figure 2). Although differences in changes in
absenteeism were noted between ASAS20 responders
and nonresponders, the level of improvements in the
nonresponders was numerically greater than the level of
changes in responders, which might be explained by the
difference in the baseline scores between the two groups
(mean 3.1 days per month missed at baseline versus
1.4 days per month, respectively).
Similarly, in the AS and nr-axSpA subgroups, patients
achieving an ASAS20 response at week 12 reported
greater improvements in productivity, both within and
outside the home, compared to baseline. As in the over-
all axSpA population, differences in absenteeism seemed
to favor nonresponders over responders in the AS and
nr-axSpA populations; however, this may be explained
by the differences in baseline productivity loss.
For axSpA patients, the effect sizes of the changes in
productivity, measured by the SRM, in ASAS20 responders
were small (SRM < 0.5) for absenteeism, presenteeism
and days with outside help, but moderate to large for
the other WPS questions. In nonresponders, the magni-
tude of change was negligible (SRM < 0.1) or small
(SRM < 0.5) (Figure 3). Similar findings were found in
the nr-axSpA and AS subpopulations.
Work Productivity Survey changes from baseline by other
response measures at week 12
The responsiveness of the WPS when using the BAS-
DAI50 response criteria resulted in similar findings in
Table 5 Work Productivity Survey baseline scores by defined known groups: household productivity and daily
activities (randomized set, observed cases)a



























Worse Better Worse Better Worse Better Worse Better Worse Better
BASDAI
axSpA (cutoff 5.30 and 7.60) 9.36d 3.28 9.38e 5.44 6.05d 2.47 2.21f 0.78 6.00d 3.83
n = 84 n = 86 n = 84 n = 86 n = 84 n = 86 n = 84 n = 86 n = 84 n = 86
AS (cutoff 5.20 and 7.60) 8.96d 3.04 8.39f 5.28 6.07d 2.30 1.72f 0.53 5.96d 3.77
n = 46 n = 47 n = 46 n = 47 n = 46 n = 47 n = 46 n = 47 n = 46 n = 47
nr-axSpA (cutoff 5.40 and 7.60) 9.84d 3.38 10.58f 5.82 6.03e 2.51 2.82 1.08 6.05d 3.62
n = 38 n = 39 n = 38 n = 39 n = 38 n = 39 n = 38 n = 39 n = 38 n = 39
BASFI
axSpA (cutoff 3.80 and 7.00) 9.90d 2.95 9.24f 6.38 6.91d 2.71 3.01e 0.90 6.17d 3.56
n = 87 n = 84 n = 87 n = 84 n = 87 n = 84 n = 87 n = 84 n = 87 n = 84
AS (cutoff 4.40 and 7.10) 10.66d 1.93 9.98d 4.56 6.68d 2.07 2.49d 0.38 6.45d 3.56
n = 47 n = 45 n = 47 n = 45 n = 47 n = 45 n = 47 n = 45 n = 47 n = 45
nr-axSpA (cutoff 3.00 and 6.80) 9.13f 4.03 9.34 7.51 7.66e 2.78 3.53 1.70 6.16d 3.54
n = 38 n = 37 n = 38 n = 37 n = 38 n = 37 n = 38 n = 37 n = 38 n = 37
Total Spine Pain
axSpA (cutoff 6 and 8) 8.35d 2.54 8.51d 4.83 5.89d 3.03 2.06 1.78 6.09d 3.61
n = 136 n = 109 n = 136 n = 109 n = 136 n = 109 n = 136 n = 109 n = 136 n = 109
AS (cutoff 6 and 8) 7.68d 2.36 8.03e 3.91 5.14d 1.54 1.42 1.45 6.00d 3.71
n = 76 n = 56 n = 76 n = 56 n = 76 n = 56 n = 76 n = 56 n = 76 n = 56
nr-axSpA (cutoff 6 and 8) 9.20d 2.74 9.13f 5.81 6.83 4.60 2.87 2.13 6.20d 3.51
n = 60 n = 53 n = 60 n = 53 n = 60 n = 53 n = 60 n = 53 n = 60 n = 53
SF-36 PCS
axSpA (cutoff 37.35 and 27.30) 9.73d 2.23 10.85d 3.81 6.45d 2.13 3.23d 0.38 6.25d 3.28
n = 80 n = 80 n = 80 n = 80 n = 80 n = 80 n = 80 n = 80 n = 80 n = 80
AS (cutoff 36.49 and 26.73) 9.55d 1.89 11.43d 4.30 5.61e 2.00 1.39 0.45 6.32d 3.43
n = 44 n = 44 n = 44 n = 44 n = 44 n = 44 n = 44 n = 44 n = 44 n = 44
nr-axSpA (cutoff 38.25 and 27.40) 9.17d 2.61 9.72d 3.25 7.42e 2.28 5.11d 0.44 5.81d 3.00
n = 36 n = 36 n = 36 n = 36 n = 36 n = 36 n = 36 n = 36 n = 36 n = 36
SF-36 MCS
axSpA (cutoff 49.39 and 30.79) 8.88d 5.40 10.83e 6.69 8.63d 1.74 4.03e 1.28 5.94d 4.30
n = 80 n = 80 n = 80 n = 80 n = 80 n = 80 n = 80 n = 80 n = 80 n = 80
AS (cutoff 49.93 and 31.38) 8.45f 4.61 10.25f 6.43 7.41d 1.30 2.52 1.00 6.14e 4.52
n = 44 n = 44 n = 44 n = 44 n = 44 n = 44 n = 44 n = 44 n = 44 n = 44
nr-axSpA (cutoff 48.41 and 30.18) 10.36 6.36 11.64f 6.56 10.00d 2.28 5.39f 1.53 5.92f 4.19
n = 36 n = 36 n = 36 n = 36 n = 36 n = 36 n = 36 n = 36 n = 36 n = 36
ASQoL
axSpA (cutoff 9.00 and 15.00) 10.13d 2.66 10.41d 4.59 8.43d 1.29 4.21d 0.97 6.75d 3.32
n = 97 n = 90 n = 97 n = 90 n = 97 n = 90 n = 97 n = 90 n = 97 n = 90
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Table 5 Work Productivity Survey baseline scores by defined known groups: household productivity and daily
activities (randomized set, observed cases)a (Continued)
AS (cutoff 9.00 and 15.00) 9.00d 2.30 10.49d 4.30 6.96d 1.43 3.30d 0.55 6.42d 3.47
n = 53 n = 47 n = 53 n = 47 n = 53 n = 47 n = 53 n = 47 n = 53 n = 47
nr-axSpA (cutoff 9.00 and 15.00) 11.50d 3.05 10.32e 4.91 10.20d 1.14 5.30f 1.42 7.16d 3.16
n = 44 n = 43 n = 44 n = 43 n = 44 n = 43 n = 44 n = 43 n = 44 n = 43
aASQoL: Ankylosing spondylitis quality of life; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index;
MCS: Mental Components Summary; PCS: Physical Components Summary; SF-36: Short form 36 items. bCutoff points represent the first and third quartiles of
baseline scores: “Worse” state is defined for each individual measure as BASDAI score at or above the third quartile; BASFI score at or above the third quartile;
Total Back Pain score at or above the third quartile; ASQoL at or above the third quartile; SF-36 MCS at or below the first quartile; SF-36 PCS at or below the first
quartile; “better” state is defined for each individual measure as BASDAI score at or below the first quartile; BASFI score at or below the first quartile; Total Back
Pain score at or below the first quartile; ASQoL score at or below the first quartile; SF-36 MCS, PCS at or above the third quartile. cWPS Q4 is scored on a 0 to
10 scale, where 0 = no interference and 10 = complete interference. dP ≤ 0.001; eP ≤ 0.01; fP ≤ 0.05; nonparametric bootstrap-t method with a variance stabilizing
transformation, 10,000 replications.
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three populations, BASDAI50 responders at week 12 re-
ported significantly or numerically greater improvements
compared to nonresponders, except in absenteeism (in
axSpA and nr-axSpA populations) and days missed of
social activities (nr-axSpA subpopulation), where slightly
higher improvements were noticed in nonresponders
versus responders; however, this may be explained by
the differences in baseline productivity losses (data not
shown). The pattern of productivity change effect sizes
observed in BASDAI50 responders and nonresponders
were similar to those observed in ASAS20 responders
and nonresponders.
With regard to the responsiveness of WPS to more
stringent clinical responses, such as ASAS40 or ASAS50,
the effect sizes in mean changes in productivity within
and outside the home in the responder groups wereFigure 2 Mean changes from baseline in Work Productivity Survey by S
clinical response at week 12. Change from baseline in Work Productivity Su
Society 20% improvement criteria (ASAS20) clinical response at week 12 in ov
cases). *P≤ 0.05, **P≤ 0.01, #P≤ 0.001; responders versus nonresponders. P-va
interference is a score on a scale of 0 to 10 points (0 = no interference and 10moderate to large, except for two questions (absenteeism
and days with outside help) for which the effect sizes
were small (SRM < 0.5). Results were similar in the over-
all axSpA population, nr-axSpA and AS subpopulations,
except for absenteeism and days missed of social activ-
ities, which indicated different behaviors in the nr-
axSpA and AS subpopulations (data not shown).
The results based on the total and nocturnal back pain
MCID response were inconclusive because of a large im-
balance in the sample sizes of the two groups compared.
With regard to productivity changes were compared
between responders and nonresponders at week 12 de-
fined using other clinical response criteria, such as the
ASDAS CII, ASDAS MI or the BASFI MCID response
(Figure 4), clinical responders reported significantly or
numerically larger improvements in productivity within
and outside the home across all WPS questions in allpondyloArthritis International Society 20% improvement criteria
rvey (WPS) by Assessment of Ankylosing Spondyloarthritis International
erall axial spondyloarthritis (axSpA) population (randomized set, observed
lues were obtained using the nonparametric bootstrap-t method. Rate of
= complete interference). WP: Work productivity.
Figure 3 Effect size of mean changes from baseline in Work Productivity Survey by SpondyloArthritis International Society 20%
improvement criteria clinical response at week 12. Effect size (standardized response mean, SRM) of mean changes from baseline in Work
Productivity Survey (WPS) are presented by Assessment of Ankylosing Spondyloarthritis International Society 20% improvement criteria (ASAS20)
clinical response at week 12 for overall axial spondyloarthritis (axSpA) population (A), ankylosing spondyloarthritis (AS) subpopulation (B) and
nonradiographic axial spondyloarthritis (nr-axSpA) subpopulation (C) (randomized set, observed cases). SRM (absolute values) thresholds: small
(from 0.2 to 0.5; below the dashed line); moderate (from 0.5 to 0.8; between the two lines) and large (>0.8; above the solid line). WP:
Work productivity.
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effect sizes of the changes in productivity in ASDAS CII,
ASDAS MI or BASFI responders (Figure 5) were small
(SRM < 0.5) for absenteeism (WPS Q2) and days with
outside help (WPS Q8), and generally moderate to large
for the other WPS questions. In nonresponders, the
magnitude of change was negligible (SRM < 0.1) or small
(SRM < 0.5). Similar effect sizes were observed in the nr-
axSpA and AS subpopulations (data not shown).
Discussion
This work assessed the initial psychometric properties of
the WPS, originally developed in a population of patientswith RA [17], in patients with axSpA, nr-axSpA and AS.
The disease specific WPS is a tool developed to estimate
productivity limitations in the workplace and relating to
household activities due to arthritis [17] and whose psy-
chometric properties have already been demonstrated in
patients with active RA [17]. Previous work demonstrated
that the WPS could efficiently evaluate both the burden of
the disease and clinical interventions on work outcomes
in patients with RA [17,32,33].
The discriminant validity, responsiveness to clinical
changes and reliability of the survey were evaluated in
patients enrolled in a clinical trial for the treatment of
active axSpA. The OMERACT meetings 6 and 7 [34,35]
Figure 4 Mean changes from baseline in Work Productivity Survey by Bath Ankylosing Spondylitis Functional Index response at
week 12. Change from baseline in Work Productivity Survey (WPS) by Bath Ankylosing Spondylitis Functional Index (BASFI) response at week
12 in overall axial spondyloarthritis (axSpA) population (randomized set, observed cases). *P ≤ 0.05, #P ≤ 0.001, responders versus nonresponders.
P-values were obtained using the nonparametric bootstrap-t method. Rate of interference is a score on a scale of 0 to 10 points (0 = no
interference and 10 = complete interference). WP: Work productivity.
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http://arthritis-research.com/content/16/4/R164highlighted the importance to patients of consideration of
the impact of arthritic conditions on paid and unpaid work
outcomes, as these factors represent an important compo-
nent of the health and well-being of rheumatology patients.
Similar thinking should apply to patients with axSpA.
Patient-reported outcomes have long been included in
rheumatology trials, as they capture the patient’s perspective
of the disease process and the impact of treatments on the
disease. Despite being of interest to patients and employers,
the impact of axSpA or AS on work outcomes is not cur-
rently a core component of rheumatology clinical trials.
The spondyloarthritis treatment guidelines of the Can-
adian Rheumatology Association and the Spondyloarthri-
tis Research Consortium of Canada indicate that disease
monitoring should include assessments of function, dis-
ability and handicap and further noted that “[p]articipa-
tion in social, leisure, education, community and work
activities must be an integral measure used to evaluate
outcomes by health professionals, educators, policymakers
and researchers” 2279 [36]. Furthermore, the ASAS has
indicated the importance of worker productivity in its edu-
cational slides. OMERACT has reinforced the importance
of work productivity as an outcome measure in rheuma-
tology through the Worker Productivity Special Interest
Group, which has reviewed specific productivity instru-
ments and continues to evaluate concepts and methodo-
logical and interpretation issues in work productivity [37].
The present findings indicate that the WPS instrument
was generally well understood by patients, as indicated
by the high completion rates. As in rheumatoid arthritis,
the WPS demonstrated good discriminant validity, interms of both association coefficients and known-groups
analyses, evaluated against a range of different continu-
ous measures used to assess disease activity, physical
functioning and HRQoL. The association coefficients in-
dicate the divergent validity between the individual WPS
questions and the other measures considered, which was
further confirmed by the known-groups analyses. Find-
ings in the nr-axSpA and AS subpopulations were simi-
lar to those in the overall axSpA population.
The known-groups analyses based on the first and
third quartiles of the instrument scores at baseline were
further confirmed using a median cutoff of the score.
However, the responsiveness of the WPS was assessed
using clinically recognized thresholds and supports the
discriminant validity analysis.
The WPS was also responsive to clinical changes, as
measured by the ASAS20 and BASDAI50 responses at
week 12. Findings were also similar when using a range of
different clinical response measures (ASAS40, ASAS50,
ASDAS MI, ASDAS CII and BASFI MCID), supporting
the responsiveness and reliability of the WPS. Similar
results were reported in all three populations (axSpA,
nr-axSpA and AS).
All WPS questions showed a certain level of respon-
siveness to clinical changes. However, the responsive-
ness of questions concerning the number of work days
missed due to axSpA and the number of days with out-
side help hired were not as large or consistent as the
other WPS questions. The number of respondents who
actually reported full days of work missed, or days with
outside help, was quite small relative to the entire study
Figure 5 Effect size of mean changes from baseline in Work Productivity Survey by Bath Ankylosing Spondylitis Functional Index
response at week 12. Effect size (standardized response mean, SRM) of mean changes from baseline in Work Productivity Survey (WPS) are
presented by Bath Ankylosing Spondylitis Functional Index (BASFI) response at week 12 for overall axial spondyloarthritis (axSpA) population
(A), ankylosing spondyloarthritis (AS) subpopulation (B) and nonradiographic axial spondyloarthritis (nr-axSpA) subpopulation (C) (randomized
set, observed cases). SRM (absolute values) thresholds: small (from 0.2 to 0.5; below the dashed line); moderate (from 0.5 to 0.8; between the two
lines) and large (>0.8; above the solid line). WP: Work productivity.
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the impact of axSpA on productivity more likely mani-
fests as daily interference with normal working prac-
tices, without resulting in full disability. However, it
should also be noted that because 12.4% of the sample
reported being unable to work due to arthritis at base-
line, patients who might otherwise have reported miss-
ing a high number of days of work did not report their
level of absenteeism. The low level of responsiveness forthe question assessing days with hired outside help
would appear to suggest that axSpA patients might not
necessarily hire outside help, but the possibility that pa-
tients receive external help from relatives or friends
cannot be excluded.
Given the intent of using the WPS across a variety of
rheumatic conditions, including those where higher levels
of disability might be anticipated, all questions of the WPS
should remain to ensure an accurate assessment of the
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hold productivity.
The responsiveness and reliability of the WPS for use in
axSpA has been confirmed not only by the differences in
the mean changes in WPS scores but also by the effect
sizes seen for responders and nonresponders and the simi-
larities in responsiveness when using different response
criteria. This was true for the overall axSpA population as
well as the nr-axSpA and AS subpopulations.
Although there is no gold standard for assessing worker
productivity in axSpA, these results are in line with previous
work carried out for the Work Productivity and Activity
Impairment (WPAI) questionnaire in the AS subpopulation.
Similar to the current findings in the AS subpopulation, in
the previous work carried out using the WPAI, patients
with greater disease severity (assessed using BASDAI) expe-
rienced greater work impairment, presenteeism and impair-
ment in daily activities; however, absenteeism was not
significantly different between patients with worse health
compared to those with better health [38].
The limitations of this study include the patient popu-
lation, which was recruited for a clinical trial of active
axSpA and therefore may not be completely representa-
tive of the wider axSpA population. However, as the
WPS is currently developed as a tool for clinical trials,
the patient population used should provide sufficient
evidence to ensure the validity of this measure in its
current role. The WPS is also affected by the normal
limitations of self-reported questionnaires; however, pre-
vious reports have confirmed that this is still the best
means of collecting such data [39].
Conclusions
The WPS was found to be a valid instrument in axSpA,
nr-axSpA and AS on the basis of its ability to discrimin-
ate between patients with different disease symptom se-
verity and between patients who respond to recognized
clinical changes. This survey can be used to capture the
impact of active axSpA on productivity in the workplace
and within the household, as well as participation in
daily activities. It is also an informative instrument for
use in clinical trials and in clinical practice, enabling as-
sessment of the impact of treatment on axSpA-related
workplace and household productivity losses.
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